Navigation Links
Alliance for Children's Therapeutics (ACT) Presents Dalazatide Data Demonstrating Positive Response in Lupus
Date:6/10/2016

SEATTLE, June 10, 2016 /PRNewswire/ -- The Alliance for Children's Therapeutics today presented positive, updated data from an ex vivo study using KPI's Therapeutics/Kineta's lead drug Dalazatide for children and teens with lupus nephritis. The results were presented at the European League Against Rheumatism's 17th Annual Congress in London. Dr. Anne Stevens, a researcher at the Seattle Children's Research Institute, is leading the study and presented the work at the congress.

Logo - http://photos.prnewswire.com/prnh/20160609/377765LOGO

Lupus nephritis is an autoimmune disease which causes kidney inflammation and damage. Current medications are effective in reducing some of the inflammation associated with the disease, but they also suppress normal functions of the immune system, an undesirable side effect that is particularly problematic in children.

In particular, effector memory T cells associated with development of other autoimmune diseases such as psoriasis, inflammatory bowel diseases and rheumatoid arthritis appear to play an important role in lupus nephritis. T cells secrete inflammatory mediators (cytokines) that cause tissue damage and inflammation.  T cells and B cells can amplify inflammatory responses thereby causing damage to the otherwise healthy tissue.

"New study data shows that patients with active lupus nephritis express higher levels of the Kv 1.3 channel, the target of Dalazatide, than do patients with inactive disease or healthy volunteers," said Dr. Stevens. "T cells from patients with active lupus are sensitive to blockade by Dalazatide, demonstrating ex vivo efficacy of the drug, and provide data to support the design of a clinical trial in patients with lupus," Dr. Stevens added.

"Lupus patients are in urgent need of novel and more effective therapies," said Dr. Charles Magness, President and CEO of KPI Therapeutics. "We are very encouraged by the positive effect Dalazatide has demonstrated in this study and are working to advance Dalazatide into lupus and lupus nephritis clinical trials."

The updated data also demonstrated that Dalazatide can decrease a group of cytokines functioning as biomarkers associated with active lupus disease. Importantly, these results show that Dalazatide has the ability to suppress these cytokines which are associated with disease inflammation and damage to lupus patients to a degree similar to traditional but toxic therapies such as cyclosporine A.

Link to poster

About Dalazatide
Dalazatide completed a Phase 1B clinical trial in plaque psoriasis. It has a novel mechanism of action (MOA). Preclinical and clinical data have shown that Dalazatide is a selective and potent blocker of the voltage-gated Kv1.3 potassium channel - a key channel in the activation of effector-memory T cells. Effector memory T cells are implicated in the pathology of many autoimmune diseases. Dalazatide was the first specific Kv1.3 inhibitor advanced into human clinical trials. Dalazatide is being studied as a potential therapy for autoimmune diseases including lupus, ANCA Vasculitis, multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, type 1 diabetes, inflammatory bowel diseases, and asthma. Dalazatide is being developed jointly with Kineta Inc.

About KPI Therapeutics
KPI Therapeutics is a clinical stage biotechnology company which develops first in class therapies for unmet medical needs in autoimmunity and chronic pain. KPI leads an alliance of development partners under a common purpose to drive focused and efficient drug development. KPI partners include Kineta, Inc, Chimera Biotec, Life Chemicals, MPI Research, Medical Marketing Economics, CoMotion, the University Of Washington School Of Medicine and the Alliance for Children's Therapeutics which includes Seattle Children's Research Institute. With its lead development partner Kineta, Inc, KPI is advancing the development of Dalazatide (systemic autoimmune diseases including lupus) and CSP conopeptides (chronic pain). For more information about KPI please visit our website: kpitherapeutics.com

About Kineta
Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding KPI's plans for future research and development activities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent to KPI's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, successful completion of clinical testing, and achievement of regulatory approval. All forward-looking statements are qualified in their entirety by this cautionary statement, and KPI undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact Jacques Bouchy, SVP Business Development & Corporate Communications
Kineta Inc.
Email
(206) 378-0400

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alliance-for-childrens-therapeutics-act-presents-dalazatide-data-demonstrating-positive-response-in-lupus-300282896.html


'/>"/>
SOURCE Alliance for Children’s Therapeutics (ACT)
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Partnering Deals and Alliances of Sun Pharmaceutical 2010-2016
2. Decision Resources Group Expands Product Sales in Latin America through Strategic Alliance with Close-Up International
3. Community Oncology Alliance Letter on Medicare Part B Drug Payment Model
4. Statement from the Patients Alliance for Drug Safety Protections on the Need for Restricted Distribution Systems for High-Risk Medicines
5. Aptuit and Icagen Agree to Strategic Alliance
6. Pharmaceutical packaging industry leaders form the Matrix Alliance to help manufacturers speed breakthrough treatments to market
7. Alliance Health Leverages CAKE by Accelerize to Support Growing Business
8. Psyche Systems Corporation Forms Strategic Alliance with tevixMD to Provide Patient Validation and Verification in the Lab
9. Advinus Therapeutics, a TATA Enterprise, Meets Milestone in Drug Discovery Alliance
10. Business alliance in pharmaceutical additives between SPI Pharma and Asahi Kasei Chemicals
11. TB Alliance and Partners Announce Worlds First Availability of Appropriate, Child-friendly TB Medicines in Correct Doses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/4/2017)... , Aug. 4, 2017 The search for ... after a physician/patient consult has long been the goal ... a notable focus of the largest meeting of lab ... to healthcare market research firm Kalorama Information.  The firm ... (POCT) offerings or related supplies and software were at ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... The ... a three-year grant totaling $975,000, renewing its funding from the Health Resources and ... , This funding marks, the fourth time the HRSA administration has renewed its ...
(Date:8/16/2017)... Linda, Ca (PRWEB) , ... August 16, 2017 , ... ... innovators, engineers, and scientists from around the world, is excited to announce Andrew Ly ... him in his academic pursuits, covering textbook costs. , Ly, who is in ...
(Date:8/16/2017)... ... , ... With a new PD diagnosis every nine minutes, research is critical ... are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board ... in all areas relevant to PD research. The SAB meets annually to review ...
(Date:8/16/2017)... ... , ... Melbourne’s reign as the world’s most liveable city has been extended ... Index. , The Index surveys 140 of the world’s cities and Melbourne has come ... come in the top three of the index. So what is it that keeps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Harbor Retirement ... Beach, announced today that two of their associates were recognized with individual “Best ... senior living communities in Florida. The awards were announced at the 5th Annual ...
Breaking Medicine News(10 mins):